Wedbush Downgrades Stemline Therapeutics (STML) to Neutral, Following Acquisition
- Nasdaq, S&P 500, set records as jobless claims decline
- Moderna (MRNA) Tops Q2 Street Estimates, Nabs $4.2 Billion from 199 Million Sold Vaccines That Yielded 93% Efficacy Through Six Months
- Oil rises over 1% as Mideast tensions face virus concerns
- Penn National Gaming (PENN) 'Scores' with $2 Billion Deal to Acquire theScore (SCR), Seen as 'Highly Strategic'
- Uber (UBER) Beats Estimates As Higher Labor Spend Drags on Profitability, Analysts Lower PTs but Remain Bullish
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Wedbush analyst David Nierengarten downgraded Stemline Therapeutics (NASDAQ: STML) from Outperform to Neutral with a price target of $12.50 (from $11.00).
Shares of Stemline Therapeutics closed at $4.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: RBC Capital Downgrades Karyopharm Therapeutics (KPTI) to Sector Perform
- Nevro (NVRO) Crashes 25% After Withdrawing FY Outlook, 5 Firms Downgrade as Near-Term Visibility Remains Challenged
- BofA Securities Downgrades Cardinal Health (CAH) to Underperform, Following Earnings
Create E-mail Alert Related CategoriesDowngrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!